Since dual inhibition targeting EGFR and YAP could provide better therapeutic effect than single inhibition of each 12, we set out to explore if the combination of YAP and EGFR inhibition reverses chemotherapy resistance in colorectal cancer. The gene discussed is YAP1; the disease is colorectal cancer.